Latest From GlycoMimetics Inc.
BeiGene’s license agreement with Leap Therapeutics covers Asia, except for Japan, along with Australia and New Zealand. Apollomics obtains rights in China and beyond to GlycoMimetics’ e-selectin antagonists.
Three new drugs for sickle cell disease could be on the market in the US next year, representing a groundswell of advancement for the devastating blood disorder that has had limited options.
The company's NDA for voxelotor was accepted by the US FDA for priority review with action expected in February, setting up a showdown with Novartis.
After a long wait, the top-line data for Pfizer’s RESET study of the investigational treatment for sickle cell disease disappoint. Shares in rivipansel’s originator GlycoMimetics halved on the news.
- Drug Discovery Tools
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- North America
- Parent & Subsidiaries
- GlycoMimetics Inc.
- Senior Management
Rachel K King, CEO
Brian Hahn, SVP, CFO
John Magnani, PhD, SVP, Research & CSO
Armand Girard, SVP, Strategy & Corp. Dev.
Eric Feldman, MD, VP, Clinical Dev.
- Contact Info
Phone: (240) 243-1201
9708 Medical Center Dr.
Rockville, MD 20850
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.